Equities analysts forecast that Prothena Co. PLC (NASDAQ:PRTA) will report sales of $280,000.00 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Prothena’s earnings. The lowest sales estimate is $260,000.00 and the highest is $300,000.00. Prothena reported sales of $230,000.00 during the same quarter last year, which would suggest a positive year-over-year growth rate of 21.7%. The firm is expected to report its next quarterly earnings results after the market closes on Thursday, February 14th.
On average, analysts expect that Prothena will report full-year sales of $1.00 million for the current fiscal year, with estimates ranging from $990,000.00 to $1.00 million. For the next financial year, analysts anticipate that the company will post sales of $25.95 million, with estimates ranging from $900,000.00 to $51.00 million. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Prothena.
Several brokerages have issued reports on PRTA. Oppenheimer reissued a “hold” rating on shares of Prothena in a research report on Sunday, November 11th. BidaskClub cut Prothena from a “hold” rating to a “sell” rating in a research report on Tuesday, November 13th. Cantor Fitzgerald reissued an “overweight” rating on shares of Prothena in a research report on Friday, November 23rd. ValuEngine raised Prothena from a “sell” rating to a “hold” rating in a research report on Thursday, December 13th. Finally, Zacks Investment Research raised Prothena from a “hold” rating to a “strong-buy” rating and set a $13.00 target price on the stock in a research report on Tuesday, January 8th. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and four have assigned a buy rating to the company’s stock. Prothena presently has a consensus rating of “Hold” and a consensus price target of $36.22.
Prothena stock opened at $12.75 on Thursday. Prothena has a one year low of $8.63 and a one year high of $44.75. The firm has a market cap of $509.86 million, a P/E ratio of -3.13 and a beta of 2.56.
Prothena Company Profile
Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on the discovery, development, and commercialization of novel immunotherapies for the treatment of diseases in the neuroscience and orphan categories. The company is developing antibody-based product candidates that include NEOD001, a monoclonal antibody that is in Phase III and Phase IIb clinical trials for the treatment of AL amyloidosis; PRX002/RG7935 that is in Phase II clinical trial for treating Parkinson's disease and other related synucleinopathies; and PRX004, a monoclonal antibody that is under preclinical development for the treatment of ATTR Amyloidosis.
Featured Article: Discount Rate
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Prothena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena and related companies with MarketBeat.com's FREE daily email newsletter.